Free Trial
NASDAQ:INZY

Inozyme Pharma Q1 2025 Earnings Report

Inozyme Pharma logo
$3.99 0.00 (0.00%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$3.99 0.00 (0.00%)
As of 06/6/2025 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inozyme Pharma EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Inozyme Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inozyme Pharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Inozyme Pharma's Q1 2025 earnings is scheduled for Tuesday, August 5, 2025

Earnings Documents

Inozyme Pharma Earnings Headlines

BMRN to Acquire Inozyme Pharma
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Inozyme Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inozyme Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inozyme Pharma and other key companies, straight to your email.

About Inozyme Pharma

Inozyme Pharma (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

View Inozyme Pharma Profile

More Earnings Resources from MarketBeat